National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Adverse Drug Events (ADE) (2)
- Behavioral Health (2)
- Evidence-Based Practice (1)
- Guidelines (1)
- Healthcare Utilization (2)
- (-) Hepatitis (7)
- (-) Human Immunodeficiency Virus (HIV) (7)
- Medication (4)
- Opioids (1)
- Patient-Centered Outcomes Research (1)
- Patient Adherence/Compliance (1)
- Patient Safety (1)
- Primary Care (1)
- Risk (1)
- Screening (1)
- Sexual Health (1)
- Substance Abuse (1)
- Training (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 7 of 7 Research Studies DisplayedTsui JI, Akosile MA, Lapham GT
Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV.
Hepatitis C and HIV are associated with opioid use disorders (OUD) and injection drug use. Medications for OUD can prevent the spread of HCV and HIV. The objective of this retrospective observational cohort study was to describe the prevalence of documented OUD, as well as receipt of office-based medication treatment, among primary care patients with HCV or HIV.
AHRQ-funded; HS026369.
Citation: Tsui JI, Akosile MA, Lapham GT .
Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV.
J Gen Intern Med 2021 Apr;36(4):930-37. doi: 10.1007/s11606-020-06389-7..
Keywords: Opioids, Medication, Substance Abuse, Behavioral Health, Hepatitis, Human Immunodeficiency Virus (HIV), Primary Care
Wang D
A comparison of in-person and online training in a statewide clinical education program for dissemination of HIV, HCV and STD clinical evidence.
This study compared in-person and online training for dissemination of clinical evidence of HIV, HCV, and STD. The study used 250 clinicians completing four training courses in dual formats over a three-month period. Online training was the preferred format by clinicians.
AHRQ-funded; HS022057.
Citation: Wang D .
A comparison of in-person and online training in a statewide clinical education program for dissemination of HIV, HCV and STD clinical evidence.
Stud Health Technol Inform 2019 Aug 21;264:2003-04. doi: 10.3233/shti190756..
Keywords: Human Immunodeficiency Virus (HIV), Hepatitis, Sexual Health, Evidence-Based Practice, Training, Patient-Centered Outcomes Research
Lo Re VR, Zeldow B, Kallan MJ
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.
This cohort study was conducted to determine if cumulative mitochondrial toxic nucleoside reverse transcriptase inhibitors (mtNRTI) use increased the risk of hepatic decompensation and death among patients coinfected with human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). The findings suggest that cumulative mtNRTI use may increase the risk of hepatic decompensation and death in HIV/HCV coinfection and should be avoided when alternatives exist for HIV/HCV patients.
AHRQ-funded; HS018372.
Citation: Lo Re VR, Zeldow B, Kallan MJ .
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.
Pharmacoepidemiol Drug Saf 2017 Oct;26(10):1172-81. doi: 10.1002/pds.4258..
Keywords: Adverse Drug Events (ADE), Hepatitis, Human Immunodeficiency Virus (HIV), Medication, Patient Safety
Tetrault JM, Tate JP, Edelman EJ
Hepatic safety of buprenorphine in HIV-Infected and uninfected patients with opioid use disorder: the role of HCV-infection.
The purpose of this paper was to examine risk for buprenorphine (BUP)-associated hepatotoxicity among individuals with HIV and HCV. The authors found that liver enzymes and total bilirubin are rarely elevated in HIV-infected and uninfected patients receiving BUP, and that the risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring.
AHRQ-funded; HS021112; HS018372.
Citation: Tetrault JM, Tate JP, Edelman EJ .
Hepatic safety of buprenorphine in HIV-Infected and uninfected patients with opioid use disorder: the role of HCV-infection.
J Subst Abuse Treat 2016 Sep;68:62-7. doi: 10.1016/j.jsat.2016.06.002.
.
.
Keywords: Adverse Drug Events (ADE), Hepatitis, Human Immunodeficiency Virus (HIV), Medication, Risk
Crowell TA, Berry SA, Fleishman JA
AHRQ Author: Fleishman JA
Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.
The purpose of this study is to characterize the impact of hepatitis coinfection on utilization of primary HIV care, mental health, and inpatient services. It found no difference in primary HIV care utilization according to hepatitis serostatus. However, patients with HIV/HCV coinfection demonstrated higher rates of mental health visits than any of the other groups examined.
AHRQ-authored; AHRQ-funded; ; 290201100007C.
Citation: Crowell TA, Berry SA, Fleishman JA .
Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.
J Acquir Immune Defic Syndr 2015 Apr;68(4):425-31. doi: 10.1097/qai.0000000000000490..
Keywords: Human Immunodeficiency Virus (HIV), Hepatitis, Healthcare Utilization, Behavioral Health
Zhang S, Rust G, Cardarelli K
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
The purpose of this study was to quantify the clinical and economic benefits of adherence to anti-retroviral therapy (ART), with a special focus on the subset of Medicaid enrollees with both HIV and HCV coinfection. It found that high-adherence to ART among Medicaid-enrolled patients with HIV and HCV coinfection is achievable – over 60 percent of such patients in this data-set had over 95 percent adherence to their ART.
AHRQ-funded; HS022444.
Citation: Zhang S, Rust G, Cardarelli K .
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
AIDS Care 2015;27(7):829-35. doi: 10.1080/09540121.2015.1021745..
Keywords: Hepatitis, Human Immunodeficiency Virus (HIV), Patient Adherence/Compliance, Medication
Yehia BR, Herati RS, Fleishman JA
AHRQ Author: Fleishman JA
Hepatitis C virus testing in adults living with HIV: a need for improved screening efforts.
The authors sought to understand hepatitis C virus (HCV) testing practices in people living with HIV (PLWH) in order to improve compliance with guidelines and help identify areas for future intervention. They concluded that additional efforts to improve compliance with HCV testing guidelines are needed.
AHRQ-authored; AHRQ-funded; 290201100007C.
Citation: Yehia BR, Herati RS, Fleishman JA .
Hepatitis C virus testing in adults living with HIV: a need for improved screening efforts.
PLoS One 2014 Jul 17;9(7):e102766. doi: 10.1371/journal.pone.0102766.
.
.
Keywords: Guidelines, Healthcare Utilization, Hepatitis, Human Immunodeficiency Virus (HIV), Screening